Search

everythinglearnresearchcommunity

for

Search:↓

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Tofacitinib may help regrow hair in alopecia areata patients.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Inhibiting the PI3K/Akt pathway may help prevent radiation-induced liver injury.

The study concludes that certain domains in Clostridium histolyticum enzymes are structurally unique, bind calcium to become more stable, and play distinct roles in breaking down collagen, with potential applications in medicine and drug delivery.

Infants with severe KID syndrome may be more prone to serious infections and need close monitoring.

A new mutation in the HJV gene was found in a young woman with juvenile hemochromatosis, causing unusual symptoms like secondary hypothyroidism.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

Keratin 17 is important for skin's response to radiation, affecting many genes and cell division.

Too much IKZF1 and Ikaros protein may cause alopecia areata.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

New medications could improve treatment for severe alopecia areata in Australia.

NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.

Mice with extra PKCδ resist chemical-induced skin cancer but not UV-induced.

SQSTM1 is linked to increased risk of alopecia areata.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

The study found that minor protein differences between curved and straight Japanese hair are unlikely to significantly affect hair structure.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

ZPK helps skin cells mature and may affect skin health.

CD2 might be a new treatment target for patchy alopecia areata.

The document's conclusion cannot be provided because the content is not accessible.